Invitrogen plans to develop 2D gel electrophoresis technology for applications in proteomics using protein synthesis technology licensed from Gryphon Sciences, an Invitrogen spokesperson said last week.
Gryphons technology, called native chemical ligation, is a method for chemically synthesizing proteins that Gryphon uses to develop therapeutics. The company announced Oct. 19 that Invitrogen had agreed to non-exclusively license the patents for the technology, which issued in February of this year.
Although the Invitrogen spokesperson declined to provide specifics, the Gryphon technology would be used to develop 2D gel equipment and reagents, which Invitrogen currently does not sell. The San Diego-based company does supply 1D gel equipment and kits for using yeast two-analysis to study protein-protein interactions.
Synthesizing proteins using the Gryphon technology only requires that a researcher know the amino acid sequence of the protein, Gryphon spokesman Alexander Lussow said. Scientists first design small peptide fragments, with functionalities ranging from carbohydrates to fluorescent tags, and then join the peptide fragments using native chemical ligation. The method can create high purity proteins containing 50 to 200 amino acids in a matter of days, Lussow said.
GeneProt has also licensed Gryphons protein synthesis technology, and uses the technique to manufacture small proteins that mimic the function of proteins discovered in patient samples. Founded in 1994, South San Franciso-based Gryphon initially sought to manufacture artificial proteins on a contract synthesis basis, but is now using the technology to develop its own therapeutic molecules, Lussow said.